Prostate Cancer Clinical Trial
— ENHANCEOfficial title:
EvaluatioN of High-intensity Focused Ultrasound (HIFU) Hemiablation and Short Term AndrogeN Deprivation Therapy Combination to Enhance Prostate Cancer Control for Intermediate Risk Localized Prostate Cancer: the ENHANCE Prospective Feasibility Trial.
The current study aims to examine the hypothesis that combining the focal effects of HIFU with the systemic effects of androgen deprivation therapy might eradicate the prostatic cancer cells by targeting the 'visible' index focus (by HIFU) and the tumour surrounding microenvironment which may contain 'invisible' foci and aberrant PCa related signalling (by androgen deprivation therapy) to enhance oncological outcomes of HIFU hemi-ablation in men with localized PCa, and consequently reducing treatment failures.
Status | Recruiting |
Enrollment | 20 |
Est. completion date | January 2025 |
Est. primary completion date | January 2025 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 40 Years to 80 Years |
Eligibility | Inclusion Criteria: - Men aged 40 and over. - Life expectancy = 10 years. - Localized, intermediate-risk PCa (according to the most recent version of the European Association of Urology Prostate Cancer Guidelines). - PI-RADS = 3 lesions in MRI (PI-RADS v2.1). - Unilateral (unifocal or multifocal) PCa or bilateral disease allowing unilateral GS 3+3 up to 1mm in the non-treated side. - Histopathologically verified PCa by any mpMRI-targeted prostate biopsy (3 cores per each target lesion + 12 random cores performed). - Any Gleason score 7 (3 + 4) (ISUP2). - Prostate specific antigen (PSA) =15 ng/ml. - Clinical stage T1c-T2b (based on MRI and/or rectal examination). - Absence of lymph node and distant metastases. - Prostate volume = 60 ml. Patient with prostate volume between 40 ml and 60 ml could be included only if lesion is located in posterior zone of the prostate. - Treatment-naive patients (received no previous treatments for PCa, apart from active surveillance). - World Health Organization (WHO) performance status of grade 0-2. - Men who are sexually active with women of chidbearing potential must use a highly effective method of contraception prior the first administration of hormonal therapy and must agree to continue using such precautions for 130 days after the final administration of the treatment. - Having signed a written informed consent form. Exclusion Criteria: - Men under the age of 40. - Life expectancy less than 10 years. - Any Gleason score =6 (3 + 3) (ISUP1). - Any Gleason score= 7 (4+3) (ISUP3). - PI-RADS < 3 lesions in MRI (PI-RADS v2.1). - Apex lesions may = 10 mm away from the urethral sphincter. - PSA >15 ng/ml. - Clinical stage > cT2b (based on MRI and rectal examination). - Evidence of extra-prostatic extension or seminal vesicle invasion. - Evidence of lymph node or distant metastases. - Prostate volume > 40 ml when lesion is located in the anterior zone of the prostate. - Prostatic calcifications or cysts whose location may interfere with effective delivery of HIFU energy. - Metal implants/stents in the urethra. - Active urinary tract infection. - Men who have previously received any form of PCa treatment (e.g. external beam radiation therapy (EBRT), brachytherapy, HIFU, cryosurgery, thermal or microwave therapy and/or hormonal therapy). - Patient treated with 5 a-reductase inhibitors in the previous 3 months and during the study. - Men who have undergone surgery for benign prostatic hyperplasia in the previous 6 months; i.e. a transurethral resection of the prostate (TURP), holmium laser enucleation (HOLEP), greenlight laser vaporization, others. - Men with an inability to tolerate a transrectal ultrasound probe or have undergone prior significant rectal surgery preventing insertion of transrectal HIFU probe. - Men unable to have MRI scanning (e.g. men with severe claustrophobia, permanent cardiac pacemaker or metallic implant which may likely contribute to significant image artefacts). - Men with renal impairment and a glomerular filtration rate (GFR) of <35 ml/min (unable to tolerate Gadolinium dynamic contrast enhanced MRI). - WHO performance status of grade 3-4 / men unfit for surgery. - Hypersensitivity to leuprorelin acetate, to other GnRH agonists or to any of the excipients. - Men with congenital long QT syndrome, congestive heart failure, frequent electrolyte abnormalities, or taking drugs known to prolong the QT interval. - Patients who previously underwent orchidectomy. - Language barriers that might hinder the communications, understanding of written and verbal information about the trial, consenting process, or completing the questionnaires. - Men refusing to sign an informed consent to participate in the trial. - Men with relative and/or absolute contraindications to androgen deprivation therapy. |
Country | Name | City | State |
---|---|---|---|
France | Institut Mutualiste Montsouris | Paris |
Lead Sponsor | Collaborator |
---|---|
Institut Mutualiste Montsouris | University of Turin, Italy |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Oncological outcome | Number of treatment failures determined after prostatic biopsy and defined as:
Any Gleason pattern =4. Any Gleason score =7. |
12 months after the HIFU session | |
Secondary | Urinary continence | Rate of men maintaining continence and becoming incontinent after treatment. Continence is defined as >0pad/day being used. Incontinence is defined conversely. | 1, 3, 6 and 12 months post-treatment | |
Secondary | Urinary continence variation | Variation of ICSmale SF score in incontinence domains (international continence society male short form questionnaire - incontinence domain is composed by six questions going from 0 (total continence) to 24 (severe incontinence). | at 1, 3, 6 and 12 months post-treatment | |
Secondary | Urinary continence proportion | Variation in continence category according to the number of pads used/day due to continence problems compared to baseline. Categories will be (full continence= 0 pads/day or security pad, mild incontinence =1pad/day, moderate incontinence= 2pads/day, severe incontinence >2pads/day). | 1,3, 6, and 12 months post-treatment | |
Secondary | Urinary voiding function variation | Urinary voiding function variation (compared to baseline) assessing changes of the IPSS (International Prostatic Symptoms Score).
The IPSS score measures if the subject has significant problems/symptoms in passing the urine/voiding the bladder. The scale goes from 0 (no symptoms or bother) to 35 (extremely severe symptoms). |
1,3, 6, and 12 months post-treatment | |
Secondary | Erectile function | Rate of men maintaining potency after treatment. Erectile function changes will be assessed using the IIEF-5 and considering potency as IIEF-5 =22 without need of any medication (PDE-5 inhibitors and/or others). | 1, 3, 6 and 12 months post-treatment | |
Secondary | Erectile function variation | Erectile function as compared to baseline using:
IIEF-5 score changes at different time points post-treatment, as compared to baseline. Proportion of men who are potent at baseline and then sustain erectile dysfunction, at 12 months. Potency is defined as an IIEF score =22 without requiring any medication. |
at 1, 3, 6 and 12 months post-treatment | |
Secondary | Ejaculatory function | Ejaculatory function compared to baseline using MSHQ-EjD questionary at time points post-treatment. | 1, 3, 6 and 12 months post-treatment as compared to baseline. | |
Secondary | Treatment toxicity and complications | Rate of men experiencing treatment related complications and toxicity. Surgical complications will be graded using the Clavien-Dindo classification. Treatment related toxicity and adverse events will be graded using the Common Terminology Criteria for reporting Adverse Events (CTCAE v5). | 12 months | |
Secondary | Additional treatment due to recurrent or persistent prostate cancer | Rate (%) of men needing to undergo further prostate cancer active treatment due to treatment failure due to biochemical recurrence according to the Phoenix criteria and biopsy proving persistence/recurrence of clinically significant PCa (defined as previously described - see Oncological outcome). | 12 months | |
Secondary | Quality of life variation | Evolution of quality of life compared to baseline at timepoints post-treatment using EQ-5D-5L questionary. | 1, 3, 6 and 12 months post-treatment. | |
Secondary | PSA variation | Serum free and total PSA levels changes | at 1, 3, 6, and 12 months post-treatment, as compared to baseline. | |
Secondary | Testosterone variation | Serum Testosterone levels changes . | at 1, 3, 6, and 12 months post-treatment, as compared to baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |